{ "items": [ "\n\n
\n \n 5 February 2021\n \n
\n\n \n\n \n\n \n \n \n \n COVID-19\n \n \n \n \n Research\n \n \n \n \n Vaccinology\n \n \n\n \n\n\n
\n \n\n \n \n \nA preprint of ongoing work to assess effectiveness of Oxford\u2019s ChAdOx1 coronavirus vaccine shows that the existing vaccine has similar efficacy against the B.1.1.7 \u2018Kent\u2019 coronavirus strain currently circulating in the UK to previously circulating variants.
\n \n\n\n \n 4 February 2021\n \n
\n\n \n\n \n\n \n \n \n \n COVID-19\n \n \n \n \n Clinical Trials\n \n \n \n \n Vaccinology\n \n \n\n \n\n\n
\n \n\n \n \n \nThe University of Oxford is to lead the first trial to explore alternating different COVID-19 vaccines, to explore the potential for flexibility in delivery and look for clues as to how to increase the breadth of protection against new virus strains.
\n \n\n\n \n 26 January 2021\n \n
\n\n \n\n \n\n \n \n \n \n COVID-19\n \n \n \n \n Vaccinology\n \n \n\n \n\n\n
\n \n\n \n \n \nToday, Andrew Pollard, Professor of Pediatric Infection and Immunity at the University of Oxford, and chief investigator of the trials of the ChAdOx1 nCoV-19 coronavirus vaccine, volunteered his time to help deliver live-saving Covid vaccinations at the newly opened NHS Vaccine Centre at the Kassam Stadium, Oxford.
\n \n\n\n \n 30 December 2020\n \n
\n\n \n \n \n\n \n \n \nThe University of Oxford welcomes the news that the UK Government has today accepted the recommendation from the Medicines and Healthcare products Regulatory Agency (MHRA) to authorise the emergency use of the ChAdOx1 nCoV-19 coronavirus vaccine in the UK.
\n \n\n\n \n 10 December 2020\n \n
\n\n \n\n \n\n \n \n \n \n COVID-19\n \n \n \n \n Vaccinology\n \n \n\n \n\n\n
\n \n\n \n \n \nUniversity of Oxford and AstraZeneca researchers present a pooled analysis of Phase 3 trials of a vaccine against SARS-CoV-2 across two different dose regimens, resulting in an average efficacy of 70.4%.
\n \n\n\n \n 9 December 2020\n \n
\n\n \n\n \n\n \n \n \n \n Awards & Appointments\n \n \n \n \n Neuromuscular Diseases\n \n \n\n \n\n\n
\n \n\n \n \n \nPepGen, a therapeutics company targeting severe neuromuscular diseases, including Duchenne muscular dystrophy (DMD), has closed a $45 million Series A funding round led by RA Capital Management with participation from Oxford Sciences Innovation (OSI), the company\u2019s original seed investor.
\n \n\n\n \n 23 November 2020\n \n
\n\n \n\n \n\n \n \n \n \n COVID-19\n \n \n \n \n Vaccinology\n \n \n\n \n\n\n
\n \n\n \n \n \nThe University of Oxford, in collaboration with AstraZeneca plc, today announces interim trial data from its Phase III trials that show its candidate vaccine, ChAdOx1 nCoV-2019, is effective at preventing COVID-19 (SARS-CoV-2) and offers a high level of protection.
\n \n\n\n \n 19 November 2020\n \n
\n\n \n\n \n\n \n \n \n \n COVID-19\n \n \n \n \n Vaccinology\n \n \n\n \n\n\n
\n \n\n \n \n \nThe ChAdOx1 nCov-2019 coronavirus vaccine, developed by teams at the University of Oxford, has been shown to trigger a robust immune response in healthy adults aged 56-69 and those over 70 years of age.
\n \n\n\n \n 18 November 2020\n \n
\n\n \n \n \n\n \n \n \nCollaboration with world-renowned research centre to accelerate development of exosome therapies for rare diseases
\n \n\n\n \n 14 November 2020\n \n
\n\n \n\n \n\n \n \n \n \n Vaccinology\n \n \n\n \n\n\n
\n \n\n \n \n \nResearchers at Oxford Vaccine Group have developed machine learning software to predict the efficacy of flu vaccines, offering huge potential for other vaccine research.
\n \n\n\n \n 22 October 2020\n \n
\n\n \n\n \n\n \n \n \n \n Neuroimaging\n \n \n \n \n Publication\n \n \n \n \n Research\n \n \n\n \n\n\n
\n \n\n \n \n \nThe launch of Lancet Child and Adolescent Health Commission - the first ever to address paediatric pain - aims to raise the profile of children\u2019s pain from early years to early adulthood.
\n \n\n\n \n 11 October 2020\n \n
\n\n \n\n \n\n \n \n \n \n Immunology\n \n \n\n \n\n\n
\n \n\n \n \n \nProfessor Paul Riley will lead the scientific vision of the first institute of its kind in the world to physically merge the disciplines of developmental biology and regenerative medicine in a common goal to treat some of the world\u2019s most prolific diseases.
\n \n\n\n \n 23 September 2020\n \n
\n\n \n\n \n\n \n \n \n \n COVID-19\n \n \n \n \n Vaccinology\n \n \n\n \n\n\n
\n \n\n \n \n \nPublic trust is key to a successful immunisation programme, writes Samantha Vanderslott in a piece for The Conversation.
\n \n\n\n \n 25 August 2020\n \n
\n\n \n\n \n\n \n \n \n \n Awards & Appointments\n \n \n \n \n Neuromuscular Diseases\n \n \n \n \n Public Engagement\n \n \n\n \n\n\n
\n \n\n \n \n \nThe awardees for the second round of the University of Oxford\u2019s Enriching Engagement funding scheme have now been announced, including a project from Paediatrics.
\n \n\n\n \n 18 August 2020\n \n
\n\n \n\n \n\n \n \n \n \n Parents & Carers\n \n \n \n \n Vaccinology\n \n \n\n \n\n\n
\n \n\n \n \n \nIn an opinion piece for The Guardian, Professor Matthew Snape discusses the initial results of his team's antibody study in the context of coronavirus risk to school children.
\n \n\n\n \n 12 August 2020\n \n
\n\n \n\n \n\n \n \n \n \n Neuromuscular Diseases\n \n \n \n \n Publication\n \n \n\n \n\n\n
\n \n\n \n \n \nOligonucleotides - short DNA or RNA molecules - have great therapeutic application for a range of diseases. Yet, their potential has not been fully unleashed because of challenges linked to efficient delivery. Read more to find out about recent developments in oligonucleotide modifications, and the platforms that may be used to deliver them to target sites.
\n \n\n\n \n 27 July 2020\n \n
\n\n \n\n \n\n \n \n \n \n Awards & Appointments\n \n \n \n \n Vaccinology\n \n \n\n \n\n\n
\n \n\n \n \n \nCongratulations to Professor Andrew Pollard who is the Winner of the Policy Engagement category in the Vice-Chancellor Innovation Awards 2020 for his work on Global policy on typhoid vaccines through research at Oxford!
\n \n\n\n \n 20 July 2020\n \n
\n\n \n\n \n\n \n \n \n \n COVID-19\n \n \n\n \n\n\n
\n \n\n \n \n \nA team of scientists at Oxford Vaccine Group (Department of Paediatrics) and Oxford University\u2019s Jenner Institute has taken the next step towards the discovery of a safe, effective and accessible vaccine against coronavirus.
\n \n\n\n \n 2 July 2020\n \n
\n\n \n\n \n\n \n \n \n \n Vaccinology\n \n \n\n \n\n\n
\n \n\n \n \n \nThe European Commission has granted Marketing Authorisation to Janssen for a new Ebola vaccine, developed in partnership with the University of Oxford.
\n \n\n\n \n 26 June 2020\n \n
\n\n \n\n \n\n \n \n \n \n COVID-19\n \n \n \n \n Vaccinology\n \n \n\n \n\n\n
\n \n\n \n \n \nThe Duke of Cambridge visits the University of Oxford\u2019s Oxford Vaccine Centre, to learn more about their work to establish a viable vaccine against COVID-19.
\n \n\n